EFFICACY OF PIRFENIDONE IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS PROGRESSION EVENTS

Abstract

Declines in per cent predicted forced vital capacity (FVC), declines in 6-min walk distance (6MWD), and respiratory hospitalizations are events associated with disease progression and mortality in idiopathic pulmonary fibrosis. The incidence of multiple events in the same patient over 12 months of pirfenidone treatment is unknown. III phase clinical trials ASCENT and CAPACITY compare disease progression event in patients treated with pirfenidone and placebo group. They proved that pirfenidone significantly reduces the rate of disease progression events and mortality after these events in 12 months when treated with pirfenidone compared to placebo.